Bridger Management LLC boosted its position in shares of Incyte Co. (NASDAQ:INCY) by 97.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 622,152 shares of the biopharmaceutical company’s stock after buying an additional 306,890 shares during the period. Incyte comprises 3.9% of Bridger Management LLC’s portfolio, making the stock its 10th biggest holding. Bridger Management LLC’s holdings in Incyte were worth $58,924,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. AMP Capital Investors Ltd boosted its holdings in shares of Incyte by 0.7% during the 3rd quarter. AMP Capital Investors Ltd now owns 72,076 shares of the biopharmaceutical company’s stock worth $8,414,000 after purchasing an additional 500 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of Incyte by 2.8% during the 3rd quarter. Amalgamated Bank now owns 20,332 shares of the biopharmaceutical company’s stock worth $2,374,000 after purchasing an additional 561 shares during the last quarter. Addison Capital Co boosted its holdings in shares of Incyte by 9.5% during the 4th quarter. Addison Capital Co now owns 6,632 shares of the biopharmaceutical company’s stock worth $628,000 after purchasing an additional 574 shares during the last quarter. Synovus Financial Corp boosted its holdings in shares of Incyte by 6.4% during the 3rd quarter. Synovus Financial Corp now owns 9,926 shares of the biopharmaceutical company’s stock worth $1,160,000 after purchasing an additional 593 shares during the last quarter. Finally, New Mexico Educational Retirement Board boosted its holdings in shares of Incyte by 3.8% during the 4th quarter. New Mexico Educational Retirement Board now owns 16,400 shares of the biopharmaceutical company’s stock worth $1,553,000 after purchasing an additional 600 shares during the last quarter. Institutional investors own 92.47% of the company’s stock.
Incyte Co. (NASDAQ INCY) opened at $94.23 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.99 and a current ratio of 4.01. Incyte Co. has a 52 week low of $80.85 and a 52 week high of $153.15. The company has a market capitalization of $19,890.00, a price-to-earnings ratio of -60.40 and a beta of 0.64.
In other Incyte news, EVP Reid M. Huber sold 1,958 shares of the company’s stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $85.55, for a total transaction of $167,506.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider David W. Gryska sold 6,760 shares of the company’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $98.87, for a total value of $668,361.20. Following the transaction, the insider now owns 20,752 shares in the company, valued at $2,051,750.24. The disclosure for this sale can be found here. Insiders have sold 15,670 shares of company stock worth $1,489,181 over the last 90 days. 17.70% of the stock is owned by insiders.
Several research analysts have recently weighed in on the company. Nomura restated a “buy” rating on shares of Incyte in a report on Thursday, February 1st. BMO Capital Markets restated a “buy” rating and set a $172.00 target price on shares of Incyte in a report on Wednesday, January 3rd. TheStreet cut Incyte from a “c-” rating to a “d+” rating in a report on Tuesday, December 5th. Royal Bank of Canada lowered their target price on Incyte from $136.00 to $120.00 and set a “sector perform” rating on the stock in a report on Tuesday, November 21st. Finally, ValuEngine upgraded Incyte from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. Incyte has an average rating of “Buy” and an average target price of $142.83.
WARNING: “Bridger Management LLC Boosts Holdings in Incyte Co. (INCY)” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://sportsperspectives.com/2018/03/12/bridger-management-llc-boosts-holdings-in-incyte-co-incy.html.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.